Managing Rheumatoid Arthritis
At Ignite Biomedical, our approach to Rheumatoid Arthritis (RA) is revolutionary. We're developing precision blood tests specifically designed to transform RA treatment, starting with our Methotrexate RA Precision Blood Test and TNFI Precision Blood Test.
Our mission is clear: address the critical challenge of treatment non-response. Currently, across FDA-approved therapies, only 36% of patients respond effectively, leaving 64% facing unnecessary side effects and financial burdens. For RA patients, this means potential irreversible joint damage and diminished quality of life.
By leveraging Liquid Bioscience's proprietary Emerge® AI platform - which has a 100% validation success rate compared to standard biomarker tools with a 90%+ failure rate - we're creating Treatment Response Predictors (TRPs) that can identify which patients will most likely benefit from specific RA treatments.
Our goal isn't just developing a test. It's about providing clinicians and patients with objective, data-driven decision support tools that can:
- Predict treatment effectiveness
- Reduce unnecessary medical interventions
- Minimize healthcare waste
- Improve patient outcomes
We're not just developing a product. We're pioneering a patient-focused approach to managing Rheumatoid Arthritis.
What is Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints, causing inflammation, pain, swelling, and stiffness. It typically affects smaller joints like those in the hands, wrists, and feet, often in a symmetrical pattern. If left untreated, RA can lead to severe joint damage and complications in other body systems.
.png)